These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 19900626)

  • 1. [Treatment adherence in inflammatory bowel disease. Strategies for improvement].
    Bermejo San José F; López San Román A; García AA
    Gastroenterol Hepatol; 2009 Oct; 32 Suppl 2():31-6. PubMed ID: 19900626
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Review article: improving adherence to medication in patients with inflammatory bowel disease.
    Robinson A
    Aliment Pharmacol Ther; 2008 Mar; 27 Suppl 1():9-14. PubMed ID: 18307644
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk factors for non-adherence to medication in inflammatory bowel disease patients.
    D'Incà R; Bertomoro P; Mazzocco K; Vettorato MG; Rumiati R; Sturniolo GC
    Aliment Pharmacol Ther; 2008 Jan; 27(2):166-72. PubMed ID: 17949472
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The problems of compliance and adherence, using the example of chronic inflammatory bowel disease].
    Zimmerer T; Siegmund SV; Singer MV
    Dtsch Med Wochenschr; 2009 Jul; 134(27):1417-24. PubMed ID: 19551607
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical impact and drivers of non-adherence to maintenance medication for inflammatory bowel disease.
    Selinger CP; Robinson A; Leong RW
    Expert Opin Drug Saf; 2011 Nov; 10(6):863-70. PubMed ID: 21548837
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Review article: how to control and improve adherence to therapy in inflammatory bowel disease.
    López-Sanromán A; Bermejo F
    Aliment Pharmacol Ther; 2006 Oct; 24 Suppl 3():45-9. PubMed ID: 16961745
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictors of medication adherence in inflammatory bowel disease.
    Ediger JP; Walker JR; Graff L; Lix L; Clara I; Rawsthorne P; Rogala L; Miller N; McPhail C; Deering K; Bernstein CN
    Am J Gastroenterol; 2007 Jul; 102(7):1417-26. PubMed ID: 17437505
    [TBL] [Abstract][Full Text] [Related]  

  • 8. May you never forget what is worth remembering: the relation between recall of medical information and medication adherence in patients with inflammatory bowel disease.
    Linn AJ; van Dijk L; Smit EG; Jansen J; van Weert JC
    J Crohns Colitis; 2013 Dec; 7(11):e543-50. PubMed ID: 23660489
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patient-centered communication to assess and enhance patient adherence to glaucoma medication.
    Hahn SR
    Ophthalmology; 2009 Nov; 116(11 Suppl):S37-42. PubMed ID: 19837259
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Adherence to glaucoma therapy].
    Renard JP; Giraud JM; Fenolland JR; May F
    J Fr Ophtalmol; 2010 Apr; 33(4):291-5. PubMed ID: 20304520
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Large-scale worldwide observational study of adherence with acne therapy.
    Dréno B; Thiboutot D; Gollnick H; Finlay AY; Layton A; Leyden JJ; Leutenegger E; Perez M;
    Int J Dermatol; 2010 Apr; 49(4):448-56. PubMed ID: 20465705
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Physician perception of patient adherence compared to patient adherence of osteoporosis medications from pharmacy claims.
    Copher R; Buzinec P; Zarotsky V; Kazis L; Iqbal SU; Macarios D
    Curr Med Res Opin; 2010 Apr; 26(4):777-85. PubMed ID: 20095797
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [New insight into medication adherence in chronic skin diseases].
    Broniarczyk-Dyła G; Pajor A
    Pol Merkur Lekarski; 2012 Dec; 33(198):378-81. PubMed ID: 23437712
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Psychosocial factors in inflammatory bowel disease.
    Talal AH; Drossman DA
    Gastroenterol Clin North Am; 1995 Sep; 24(3):699-716. PubMed ID: 8809244
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Psychological support and treatment in inflammatory bowel disease: the physician-patient relationship].
    Camacho Martel L
    Gastroenterol Hepatol; 2009 Oct; 32 Suppl 2():13-8. PubMed ID: 19900623
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Covert dose reduction is a distinct type of medication non-adherence observed across all care settings in inflammatory bowel disease.
    Mountifield R; Andrews JM; Mikocka-Walus A; Bampton P
    J Crohns Colitis; 2014 Dec; 8(12):1723-9. PubMed ID: 25263934
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Observations of nonadherence to recombinant human growth hormone therapy in clinical practice.
    Haverkamp F; Johansson L; Dumas H; Langham S; Tauber M; Veimo D; Chiarelli F
    Clin Ther; 2008 Feb; 30(2):307-16. PubMed ID: 18343269
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Therapeutic alliance, a stake in schizophrenia].
    Charpentier A; Goudemand M; Thomas P
    Encephale; 2009 Feb; 35(1):80-9. PubMed ID: 19250998
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of disease, adolescent, and family factors with medication adherence in pediatric inflammatory bowel disease.
    Reed-Knight B; Lewis JD; Blount RL
    J Pediatr Psychol; 2011 Apr; 36(3):308-17. PubMed ID: 20798185
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The state of the art in the management of inflammatory bowel disease.
    Hanauer SB; Present DH
    Rev Gastroenterol Disord; 2003; 3(2):81-92. PubMed ID: 12776005
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.